tetano
Editor, Senior Moderator
Pharmacoepidemiol Drug Saf
. 2022 Aug 10.
doi: 10.1002/pds.5523. Online ahead of print.
Thromboembolic events after Ad.26.COV2.S COVID-19 vaccine: Reports to the Vaccine Adverse Event Reporting System
Emily Jane Woo[SUP] 1 [/SUP], Adamma Mba-Jonas[SUP] 1 [/SUP], Alisha Thomas[SUP] 1 [/SUP], Bethany Baer[SUP] 1 [/SUP], Brendan Day[SUP] 1 [/SUP], Yeowon Kim[SUP] 1 [/SUP], Margarita Gomez-Lorenzo[SUP] 1 [/SUP], Narayan Nair[SUP] 1 [/SUP]
Affiliations
Abstract
Purpose: The Food and Drug Administration (FDA) has identified a potential safety concern for thromboembolic events (TEEs) after Ad.26.COV2.S COVID-19 Vaccine. We sought to characterize the frequency, severity, type, and anatomic location of TEEs reported to the Vaccine Adverse Event Reporting System (VAERS) following Ad.26.COV2.S.
Methods: Reports of TEEs after Ad.26.COV2.S were identified in VAERS, and demographics, clinical characteristics, and relevant medical history were summarized. For a subset of reports, physicians reviewed available medical records and evaluated clinical presentation, diagnostic evaluation, risk factors, and treatment. The crude reporting rate of TEEs was estimated based on case counts in VAERS and vaccine administration data.
Results: Through February 28, 2022, FDA identified 3790 reports of TEEs after Ad.26.COV2.S. Median age was 56 years, and 1938 individuals (51.1%) were female. Most reports, 2892 (76.3%), were serious, including 421 deaths. Median time to onset was 12 days post-vaccination. Obesity and ischemia were among the most commonly documented risk factors. Thrombocytopenia (platelet count less than 150 000/μl) was documented in 63 records (11.5%) and anti-platelet 4 antibodies in 25 (4.6%). Medical review identified cases of severe clot burden (e.g., bilateral, saddle, or other massive pulmonary embolism with or without cor pulmonale; lower extremity thrombus involving the external iliac, common femoral, popliteal, posterior tibial, peroneal, and gastrocnemius veins). The crude reporting rate was ~20.7 cases of TEE per 100 000 doses of Ad.26.COV2.S administered.
Conclusions: Life-threatening or fatal TEEs have been reported after Ad.26.COV2.S, including bilateral massive pulmonary embolism or other severe clot burden.
Keywords: Ad.26.COV2.S COVID-19 vaccine; SARS-CoV2; VAERS; coagulopathy; coronavirus; embolism; thrombus.
. 2022 Aug 10.
doi: 10.1002/pds.5523. Online ahead of print.
Thromboembolic events after Ad.26.COV2.S COVID-19 vaccine: Reports to the Vaccine Adverse Event Reporting System
Emily Jane Woo[SUP] 1 [/SUP], Adamma Mba-Jonas[SUP] 1 [/SUP], Alisha Thomas[SUP] 1 [/SUP], Bethany Baer[SUP] 1 [/SUP], Brendan Day[SUP] 1 [/SUP], Yeowon Kim[SUP] 1 [/SUP], Margarita Gomez-Lorenzo[SUP] 1 [/SUP], Narayan Nair[SUP] 1 [/SUP]
Affiliations
- PMID: 36065046
- DOI: 10.1002/pds.5523
Abstract
Purpose: The Food and Drug Administration (FDA) has identified a potential safety concern for thromboembolic events (TEEs) after Ad.26.COV2.S COVID-19 Vaccine. We sought to characterize the frequency, severity, type, and anatomic location of TEEs reported to the Vaccine Adverse Event Reporting System (VAERS) following Ad.26.COV2.S.
Methods: Reports of TEEs after Ad.26.COV2.S were identified in VAERS, and demographics, clinical characteristics, and relevant medical history were summarized. For a subset of reports, physicians reviewed available medical records and evaluated clinical presentation, diagnostic evaluation, risk factors, and treatment. The crude reporting rate of TEEs was estimated based on case counts in VAERS and vaccine administration data.
Results: Through February 28, 2022, FDA identified 3790 reports of TEEs after Ad.26.COV2.S. Median age was 56 years, and 1938 individuals (51.1%) were female. Most reports, 2892 (76.3%), were serious, including 421 deaths. Median time to onset was 12 days post-vaccination. Obesity and ischemia were among the most commonly documented risk factors. Thrombocytopenia (platelet count less than 150 000/μl) was documented in 63 records (11.5%) and anti-platelet 4 antibodies in 25 (4.6%). Medical review identified cases of severe clot burden (e.g., bilateral, saddle, or other massive pulmonary embolism with or without cor pulmonale; lower extremity thrombus involving the external iliac, common femoral, popliteal, posterior tibial, peroneal, and gastrocnemius veins). The crude reporting rate was ~20.7 cases of TEE per 100 000 doses of Ad.26.COV2.S administered.
Conclusions: Life-threatening or fatal TEEs have been reported after Ad.26.COV2.S, including bilateral massive pulmonary embolism or other severe clot burden.
Keywords: Ad.26.COV2.S COVID-19 vaccine; SARS-CoV2; VAERS; coagulopathy; coronavirus; embolism; thrombus.